291 related articles for article (PubMed ID: 32301356)
1. Pharmacotherapeutic Options for Chronic Refractory Cough.
Song WJ; Chung KF
Expert Opin Pharmacother; 2020 Aug; 21(11):1345-1358. PubMed ID: 32301356
[TBL] [Abstract][Full Text] [Related]
2. P2X3-Receptor Antagonists as Potential Antitussives: Summary of Current Clinical Trials in Chronic Cough.
Dicpinigaitis PV; McGarvey LP; Canning BJ
Lung; 2020 Aug; 198(4):609-616. PubMed ID: 32661659
[TBL] [Abstract][Full Text] [Related]
3. A review on the efficacy and safety of gabapentin in the treatment of chronic cough.
Ryan NM
Expert Opin Pharmacother; 2015 Jan; 16(1):135-45. PubMed ID: 25380977
[TBL] [Abstract][Full Text] [Related]
4. Looking ahead to novel therapies for chronic cough. Part 1 - peripheral sensory nerve targeted treatments.
Grabczak EM; Dabrowska M; Birring SS; Krenke R
Expert Rev Respir Med; 2020 Dec; 14(12):1217-1233. PubMed ID: 32804594
[TBL] [Abstract][Full Text] [Related]
5. Gefapixant for Refractory or Unexplained Chronic Cough?
Irwin RS; Madison JM
JAMA; 2023 Oct; 330(14):1335-1336. PubMed ID: 37694857
[No Abstract] [Full Text] [Related]
6. Clinical cough VI: the need for new therapies for cough: disease-specific and symptom-related antitussives.
Chung KF
Handb Exp Pharmacol; 2009; (187):343-68. PubMed ID: 18825350
[TBL] [Abstract][Full Text] [Related]
7. The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: a randomised placebo-controlled study.
Morice AH; Kitt MM; Ford AP; Tershakovec AM; Wu WC; Brindle K; Thompson R; Thackray-Nocera S; Wright C
Eur Respir J; 2019 Jul; 54(1):. PubMed ID: 31023843
[TBL] [Abstract][Full Text] [Related]
8. Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough.
Muccino D; Green S
Pulm Pharmacol Ther; 2019 Jun; 56():75-78. PubMed ID: 30880151
[TBL] [Abstract][Full Text] [Related]
9. Currently available cough suppressants for chronic cough.
Chung KF
Lung; 2008; 186 Suppl 1():S82-7. PubMed ID: 17909897
[TBL] [Abstract][Full Text] [Related]
10. P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study.
Abdulqawi R; Dockry R; Holt K; Layton G; McCarthy BG; Ford AP; Smith JA
Lancet; 2015 Mar; 385(9974):1198-205. PubMed ID: 25467586
[TBL] [Abstract][Full Text] [Related]
11. Gefapixant Curbs Chronic Cough.
Slomski A
JAMA; 2022 Apr; 327(16):1539. PubMed ID: 35471515
[No Abstract] [Full Text] [Related]
12. Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks.
Birring SS; Dicpinigaitis PV; Smith JA; Morice AH; McGarvey LP; Pavord ID; Nguyen AM; Schelfhout J; Li Q; Iskold B; Green SA; Philip G; Muccino DR; La Rosa C
Am J Respir Crit Care Med; 2023 Jun; 207(11):1539-1542. PubMed ID: 36996347
[No Abstract] [Full Text] [Related]
13. The Therapeutic Landscape in Chronic Cough.
Smith JA
Lung; 2024 Feb; 202(1):5-16. PubMed ID: 38127133
[TBL] [Abstract][Full Text] [Related]
14. Cough pharmacotherapy: current and future status.
Gibson PG; Ryan NM
Expert Opin Pharmacother; 2011 Aug; 12(11):1745-55. PubMed ID: 21524236
[TBL] [Abstract][Full Text] [Related]
15. Currently available antitussives.
Dicpinigaitis PV
Pulm Pharmacol Ther; 2009 Apr; 22(2):148-51. PubMed ID: 18771744
[TBL] [Abstract][Full Text] [Related]
16. Effective antitussives for the cough patient: an unmet need.
Chung KF
Pulm Pharmacol Ther; 2007; 20(4):438-45. PubMed ID: 17161637
[TBL] [Abstract][Full Text] [Related]
17. Important drugs for cough in advanced cancer.
Homsi J; Walsh D; Nelson KA
Support Care Cancer; 2001 Nov; 9(8):565-74. PubMed ID: 11762966
[TBL] [Abstract][Full Text] [Related]
18. A phase 3, randomized, double-blind, clinical study to evaluate the long-term safety and efficacy of gefapixant in Japanese adult participants with refractory or unexplained chronic cough.
Niimi A; Sagara H; Kikuchi M; Arano I; Sato A; Shirakawa M; La Rosa C; Muccino D
Allergol Int; 2022 Oct; 71(4):498-504. PubMed ID: 35752582
[TBL] [Abstract][Full Text] [Related]
19. The Efficacy and Safety of Gefapixant in a Phase 3b Trial of Patients with Recent-Onset Chronic Cough.
McGarvey L; Sher M; Shvarts YG; Lu S; Wu WC; Xu P; Schelfhout J; La Rosa C; Nguyen AM; Reyfman PA; Afzal AS
Lung; 2023 Apr; 201(2):111-118. PubMed ID: 36879087
[TBL] [Abstract][Full Text] [Related]
20. The pharmacology of cough.
Reynolds SM; Mackenzie AJ; Spina D; Page CP
Trends Pharmacol Sci; 2004 Nov; 25(11):569-76. PubMed ID: 15491779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
